Syantra, Inc., a leading biotechnology company developing groundbreaking cancer detection tools, has announced a new partnership with the Alamo Breast Cancer Foundation (ABCF), a nonprofit organization committed to advancing breast cancer prevention, treatment, and care for all women. This collaboration focuses on combining innovative technology with expanded access to detection and treatment. Both organizations share a common vision of developing new methods for early detection, improving treatment effectiveness, and ensuring women from all backgrounds have access to quality care. The partnership will involve dedicated funding, advocacy for relevant legislation, and substantial in-kind support from ABCF leaders and advocates.
Together, Syantra and ABCF also plan to increase public awareness about screening and treatment options for women with dense breast tissue, a condition affecting more than 43 percent of women over 40 according to research published in the Journal of the National Cancer Institute. Another major objective is reaching underserved populations who face barriers to conventional care such as mammography due to financial or logistical challenges.
Health Technology Insights: Hippocratic AI Selects Fivetran to Power Trusted Data Infrastructure for AI in Healthcare
Rob Lozuk, CEO of Syantra, emphasized that ABCF is their first advocacy partner, making this collaboration unique. He noted that the organization’s global network of medical experts, scientists, and patient advocates makes ABCF an ideal partner for advancing their mission. The collaboration will expand a current clinical study at the Mays Cancer Center at The University of Texas Health Science Center in San Antonio, which is also supported by an Alberta Innovates award Syantra received in January 2025. By working together, the two organizations aim to increase both the volume and diversity of data collected, support the clinical use of the Onco-ID Breast test, and promote reimbursement opportunities with early adopters and major insurers.
Health Technology Insights: Wolters Kluwer Launches Ovid Synthesis Expert AI
Jerry Worden, ABCF Board Member, stated that the foundation’s goal is to provide deeper and broader access to testing and treatment, reaching more women across different ages and locations while enhancing the accuracy and effectiveness of breast cancer detection. He highlighted that Syantra’s Onco-ID Breast test has the potential to detect small tumors and identify cancers often missed in mammograms. Syantra’s proprietary Onco-ID platform identifies active cancer signals by measuring the expression of a specific combination of genes using a custom multiplexed qPCR method, with data analysis supported by machine learning algorithms. Lozuk added that this partnership represents a new dimension for Syantra, combining scientific expertise with ABCF’s deep understanding of advocacy to bring the technology from the laboratory to legislation and ultimately to patients and healthcare providers who will benefit most from earlier detection and improved outcomes.
Health Technology Insights: Cardiosense Shows AI Heart Failure Data at Transcatheter Cardiovascular Therapeutics 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
